In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size

被引:45
作者
Liu, Guangpu [1 ]
Zhang, Dianrui [1 ]
Jiao, Yang [2 ]
Guo, Hejian [1 ]
Zheng, Dandan [1 ]
Jia, Lejiao [1 ]
Duan, Cunxian [1 ]
Liu, Yue [1 ]
Tian, Xiaona [1 ]
Shen, Jingyi [1 ]
Li, Caiyun [1 ]
Zhang, Qiang [3 ]
Lou, Hongxiang [2 ]
机构
[1] Shandong Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Jinan 250012, Peoples R China
[2] Shandong Univ, Sch Pharmaceut Sci, Dept Nat Prod Chem, Jinan 250012, Peoples R China
[3] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China
关键词
Riccardin D; Nanosuspensions; Nanocrystal; Pharmacokinetics; Tissue distribution; TISSUE DISTRIBUTION; BODY DISTRIBUTION; MACROCYCLIC BISBIBENZYL; IV INJECTION; NANOPARTICLES; DELIVERY; BIFENDATE; DRUGS; PHARMACOKINETICS; BIOAVAILABILITY;
D O I
10.1016/j.colsurfb.2012.09.006
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Riccardin D (RD) is a novel compound extracted from Chinese liverwort Marchantia polymorpha L. It exhibits various anticancer activities and can be used during lung cancer treatment. However, the compound's low solubility hinders its development. Recently nanosuspension has been developed as one of the most promising formulations for poorly water-soluble drugs. In order to understand the dissolution behavior of riccardin D in vitro and in vivo, two nanosuspensions of riccardin D with markedly different sizes were prepared. The particle size of nanosuspension A prepared by bottom-up method was 184.1 +/- 3.15 nm, while that of nanosuspension B prepared by top-down method was 815.4 +/- 9.65 nm. The main purpose of this study was to investigate the effects of particle size on pharmacokinetics and tissue distribution after intravenous administration. Riccardin D dissolving in organic solution was studied as control group. In pharmacokinetics study in Wistar rats, nanosuspension A showed properties similar to the control group, while nanosuspension B exhibited rather different properties. In tissue distribution research on Kunming strain mice, nanosuspension A had a multi-peak phenomenon because of reticulate endothelial system (RES) while nanosuspension B showed a high uptake in RES organs that passively target to the lungs. In conclusion, particle size of riccardin D nanosuspensions had obvious effects on pharmacokinetics and tissue distribution. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:620 / 626
页数:7
相关论文
共 40 条
[1]   Excipient-drug interactions in parenteral formulations [J].
Akers, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (11) :2283-2300
[2]   Nanonization strategies for poorly water-soluble drugs [J].
Chen, Huabing ;
Khemtong, Chalermchai ;
Yang, Xiangliang ;
Chang, Xueling ;
Gao, Jinming .
DRUG DISCOVERY TODAY, 2011, 16 (7-8) :354-360
[3]   Nanomedicine: Techniques, potentials, and ethical implications [J].
Ebbesen, Mette ;
Jensen, Thomas G. .
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2006,
[4]   Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions [J].
Gao, Lei ;
Zhang, Dianrui ;
Chen, Minghui ;
Duan, Cunxian ;
Dai, Wenting ;
Jia, Lejiao ;
Zhao, Wenfa .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 355 (1-2) :321-327
[5]   Preparation of a chemically stable quercetin formulation using nanosuspension technology [J].
Gao, Lei ;
Liu, Guiyang ;
Wang, Xiaoqing ;
Liu, Fei ;
Xu, Yuefang ;
Ma, Jing .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 404 (1-2) :231-237
[6]   Dendrimers: Novel polymeric nanoarchitectures for solubility enhancement [J].
Gupta, U ;
Agashe, HB ;
Asthana, A ;
Jain, NK .
BIOMACROMOLECULES, 2006, 7 (03) :649-658
[7]   Production and characterization of a budesonide nanosuspension for pulmonary administration [J].
Jacobs, C ;
Müller, RH .
PHARMACEUTICAL RESEARCH, 2002, 19 (02) :189-194
[8]   Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies [J].
Jia, Lejiao ;
Zhang, Dianrui ;
Li, Zhenyu ;
Duan, Cunxian ;
Wang, Yancai ;
Feng, Feifei ;
Wang, Feihu ;
Liu, Yue ;
Zhang, Qiang .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2010, 80 (02) :213-218
[9]  
Lipinski C.A., 2002, AM PHARM REV, V5, P82, DOI DOI 10.1016/S0338-9898(02)80223-2
[10]   Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology [J].
Liu, Guangpu ;
Zhang, Dianrui ;
Jiao, Yang ;
Zheng, Dandan ;
Liu, Yue ;
Duan, Cunxian ;
Jia, Lejiao ;
Zhang, Qiang ;
Lou, Hongxiang .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 422 (1-2) :516-522